# Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

> **NCT00003253** · PHASE2 · UNKNOWN · sponsor: **Oncotech** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** paclitaxel
- **OTHER:** antitumor drug screening assay

## Key facts

- **NCT ID:** NCT00003253
- **Lead sponsor:** Oncotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2013-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003253, "Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*